Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2024)

The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study

Peto L. et al, (2024)

The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study

Peto L. et al, (2024)

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.

Pessoa-Amorim G. et al, (2024), Trials, 25

High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.

Peto L. et al, (2024), Lancet, 403, 1339 - 1340

The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study

Peto L. et al, (2024)

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group None. et al, (2024)

Community involvement in an outbreak - One year on for mpox.

Cheyne A. et al, (2023), Clin Infect Dis

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914

Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial

LANDRAY M. et al, (2023), Lancet Child and Adolescent Health

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk None. and RECOVERY Collaborative Group None., (2023), Lancet, 401, 1499 - 1507

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Horby PW. et al, (2023)

Randomised controlled trials for mpox in endemic countries.

Rojek A. et al, (2023), Lancet Infect Dis

Microbial diversity and antimicrobial resistance in faecal samples from acute medical patients assessed through metagenomic sequencing.

Yokoyama M. et al, (2023), PLoS One, 18

Virus Detection and Identification in Minutes Using Single-Particle Imaging and Deep Learning.

Shiaelis N. et al, (2022), ACS Nano

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368

Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trial.

Peto L. et al, (2022), Adv Biol Regul

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676

Load More

Include forthcoming?